Home › NDC Lookup › RxCUI directory › RxCUI 2637465

Niraparib 300 MG Oral Tablet — RxCUI 2637465

RxNorm drug concept · Semantic clinical drug
RxCUI 2637465 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2637465
Official nameNiraparib 300 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asniraparib 300 MG (as niraparib tosylate monohydrate 478 MG) Oral Tablet
FDA products mapped3
Package NDCs mapped5
Reported Medicaid activity (SDUD)523 prescriptions · 7 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Niraparib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Zejula isn't a cure, but it's an important tool. It's used as 'maintenance therapy,' which means you take it after chemotherapy has already knocked back your cancer, to help keep i...
  • What exactly is Zejula supposed to do for me — is it curing my cancer?
  • You can take Zejula with or without food, so that part is flexible. Taking it with a high-fat meal does increase how much your body absorbs, but your prescriber will have set your...
  • Do I need to take it with food or at a specific time of day?
📖 Read our full Niraparib guide →

🕸️ Concept Web — How Niraparib 300 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Niraparib 300 MG Oral Tablet RxCUI 2637465

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Niraparib 1918231
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zejula 1918237
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Niraparib Oral Tablet 2637448
    • Niraparib Oral Product 1918233
    • Niraparib Pill 1918234
    • Niraparib Oral Tablet [Zejula] 2640209
    • Zejula Oral Product 1918240
    • Zejula Pill 1918241
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Niraparib 300 MG SCDC · 2637464
  • Niraparib Oral Tablet SCDF · 2637448
  • Niraparib Oral Product SCDG · 1918233
  • Niraparib Pill SCDG · 1918234

Brand-Name Concepts

  • Niraparib 300 MG Oral Tablet [Zejula] SBD · 2640214
  • Niraparib 300 MG [Zejula] SBDC · 2640213
  • Niraparib Oral Tablet [Zejula] SBDF · 2640209
  • Zejula Oral Product SBDG · 1918240
  • Zejula Pill SBDG · 1918241
  • Zejula BN · 1918237

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 2637465 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00173-0909-13 30 TABLET, FILM COATED in 1 BOTTLE (0173-0909-13) ZEJULA GlaxoSmithKline LLC 2023-06-27
00173-0912-13 30 TABLET, FILM COATED in 1 BOTTLE (0173-0912-13) ZEJULA GlaxoSmithKline LLC 2023-06-27
00173-0912-61 30 TABLET, FILM COATED in 1 BOTTLE (0173-0912-61) ZEJULA GlaxoSmithKline LLC 2023-06-27
00173-0915-13 30 TABLET, FILM COATED in 1 BOTTLE (0173-0915-13) ZEJULA GlaxoSmithKline LLC 2023-06-27
00173-0915-61 30 TABLET, FILM COATED in 1 BOTTLE (0173-0915-61) ZEJULA GlaxoSmithKline LLC 2023-06-27
Observed labelers: GlaxoSmithKline LLC (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.